Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tenaya Therapeutics ( (TNYA) ) has issued an update.
On January 28, 2026, Tenaya Therapeutics disclosed that it had received a deficiency notice from Nasdaq after its common stock traded below the required $1.00 minimum bid price for 30 consecutive business days between December 12, 2025, and January 27, 2026, triggering a 180-day compliance period through July 27, 2026, during which it must restore its share price or risk potential delisting, with the possibility of an additional 180-day extension via transfer to the Nasdaq Capital Market if certain conditions are met. Separately, effective January 26, 2026, the company’s board amended and restated its 2024 Inducement Equity Incentive Plan to increase the share pool to 3,361,000 shares for equity awards used to recruit new employees or support mergers and acquisitions, underscoring Tenaya’s continued reliance on stock-based compensation to strengthen its workforce and strategic flexibility amid listing compliance pressures.
The most recent analyst rating on (TNYA) stock is a Hold with a $0.76 price target. To see the full list of analyst forecasts on Tenaya Therapeutics stock, see the TNYA Stock Forecast page.
Spark’s Take on TNYA Stock
According to Spark, TipRanks’ AI Analyst, TNYA is a Neutral.
The score is mainly held back by weak financial performance (no revenue, large losses, and persistent negative free cash flow with continued funding needs). Technicals also lean negative given the stock remains below key longer-term moving averages and MACD is negative. A meaningful offset is the positive corporate event (FDA hold lifted and encouraging interim trial update), but it does not fully counterbalance the high financial and financing risk.
To see Spark’s full report on TNYA stock, click here.
More about Tenaya Therapeutics
Tenaya Therapeutics, Inc. is a biotechnology company focused on developing therapies using equity-based incentives to attract and retain specialized talent, with its shares listed on the Nasdaq Global Select Market.
Average Trading Volume: 4,654,058
Technical Sentiment Signal: Sell
Current Market Cap: $142.9M
For detailed information about TNYA stock, go to TipRanks’ Stock Analysis page.